Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has earned an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $10.80.

Several analysts recently commented on XERS shares. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a research note on Monday, March 2nd.

Insider Transactions at Xeris Biopharma

In other news, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $5.99, for a total transaction of $99,835.33. Following the sale, the insider owned 1,209,840 shares of the company’s stock, valued at approximately $7,246,941.60. This trade represents a 1.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Aloysius Brady sold 10,834 shares of the firm’s stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $5.54, for a total value of $60,020.36. Following the sale, the director directly owned 89,166 shares in the company, valued at $493,979.64. This trade represents a 10.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 60,835 shares of company stock worth $388,194 in the last ninety days. 6.47% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new stake in shares of Xeris Biopharma during the 4th quarter worth about $25,000. AlphaQuest LLC acquired a new stake in shares of Xeris Biopharma during the 3rd quarter worth about $35,000. Caitong International Asset Management Co. Ltd raised its position in shares of Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after acquiring an additional 7,421 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after acquiring an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after buying an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Trading Down 1.5%

Shares of XERS stock opened at $5.95 on Friday. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.19 and a quick ratio of 1.57. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -594.41 and a beta of 0.77. The stock has a 50 day simple moving average of $6.01 and a 200-day simple moving average of $7.10. Xeris Biopharma has a 1-year low of $4.13 and a 1-year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The business had revenue of $85.81 million during the quarter, compared to the consensus estimate of $86.00 million. On average, equities research analysts expect that Xeris Biopharma will post 0.12 EPS for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.